Dexamethasone (6 mg/m2/day) and prednisolone (60 mg/m2/day) were equally effective as induction therapy for childhood acute lymphoblastic leukemia in the EORTC CLG 58951 randomized trial

Haematologica

Volumn 99, Issue 7, 2014, Pages 1220-1227

  Domenech, Carine ^a   Suciu, Stefan ^b   De Moerloose, Barbara ^c   Mazingue, Françoise ^d   Plat, Geneviève ^e   Ferster, Alina ^f   Uyttebroeck, Anne ^g   Sirvent, Nicolas ^h   Lutz, Patrick ^d   Yakouben, Karima ⁱ   Munzer, Martine ^j   Röhrlich, Pierre ^k   Plantaz, Dominique ^l   Millot, Frederic ^m   Philippet, Pierre ^d   Dastugue, Nicole ^e   Girard, Sandrine ⁿ   Cavé, Hélène ⁱ   Benoit, Yves ^c   Bertrand, Yves ^a  

^a UNIVERSITÉ LYON 1   (France)

^b EORTC DATA CENTER   (Belgium)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

^d Department of Pediatric Hematology Oncology CHR ^*  (Belgium)

^e HÔPITAL DES ENFANTS   (France)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^g HOP UNIV DES ENFANTS REINE FABIOLA   (Belgium)

^h Department of Vascular and Thoracic Surgery Arnaud   (France)

ⁱ HÔPITAL ROBERT DEBRÉ   (France)

^j AMERICAN HOSPITAL OF PARIS   (France)

^k UNIVERSITY HOSPITAL OF BESANÇON   (France)

^l CHU La Tronche and University   (France)

^m J Bernard Hospital   (France)

ⁿ EDOUARD HERRIOT HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; PREDNISOLONE; ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BLEEDING; BONE NECROSIS; CHILD; CONTROLLED STUDY; DEATH; DRUG EFFICACY; DRUG TREATMENT FAILURE; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HYPERGLYCEMIA; IMMUNOPHENOTYPING; INFECTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; OVERALL SURVIVAL; PERSONALITY DISORDER; PHASE 3 CLINICAL TRIAL; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SCHOOL CHILD; THROMBOSIS; TREATMENT REFUSAL; TREATMENT RESPONSE; ADOLESCENT; CLINICAL TRIAL; INDUCTION CHEMOTHERAPY; INFANT; MORTALITY; NEWBORN; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RISK FACTOR; TREATMENT OUTCOME;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; DEXAMETHASONE; FEMALE; HUMANS; IMMUNOPHENOTYPING; INDUCTION CHEMOTHERAPY; INFANT; INFANT, NEWBORN; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREDNISOLONE; RISK FACTORS; TREATMENT OUTCOME;

EID: 84903603547     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.103507     Document Type: Article

References (29)

1. Pui CH, Mullighan CG, Evans WE, Relling MV. Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood. 2012;120(6):1165-74.
2. Ito C, Evans WE, McNinch L, Coustan-Smith E, Mahmoud H, Pui CH, et al. Comparative cytotoxicity of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. J Clin Oncol. 1996;14(8):2370-6.
3. Kaspers GJ, Veerman AJ, Popp-Snijders C, Lomecky M, Van Zantwijk CH, Swinkels LM, et al. Comparison of the antileukemic activity in vitro of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. Med Pediatr Oncol. 1996;27(2): 114-21.
4. Balis FM, Lester CM, Chrousos GP, Heideman RL, Poplack DG. Differences in cerebrospinal fluid penetration of corticosteroids: possible relationship to the prevention of meningeal leukemia. J Clin Oncol. 1987;5(2):202-7.
5. Jones B, Freeman AI, Shuster JJ, Jacquillat C, Weil M, Pochedly C, et al. Lower incidence of meningeal leukemia when prednisone is replaced by dexamethasone in the treatment of acute lymphocytic leukemia. Med Pediatr Oncol. 1991;19(4):269-75.
6. Veerman AJP, Hählen K, Kamps WA, Van Leeuwen EF, De Vaan GA, Solbu G, et al. High cure rate with a moderately intensive treatment regimen in non high-dose risk childhood acute lymphoblastic leukemia: results of protocol ALL VI from the Dutch Childhood Leukemia Study Group. J Clin Oncol. 1996;14(3):911-8.
7. Bostrom BC, Sensel MR, Sather HN, Gaynon PS, La MK, Johnston K, et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood. 2003;101:3809-17.
8. Mitchell CD, Richards SM, Kinsey SE, Lilleyman J, Vora A, Eden TO. Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol. 2005;129(6):734-45.
9. Silverman LB, Declerck L, Gelber RD, Dalton VK, Asselin BL, Barr RD, et al. Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981-1995). Leukemia. 2000;14 (12):2247-56.
10. Igarashi S, Manabe A, Ohara A, Kumagai M, Saito T, Okimoto Y, et al. No advantage of dexamethasone over prednisolone for the outcome of standard-and intermediate-risk childhood acute lymphoblastic leukemia in the Tokyo Children's Cancer Study Group L95-14 protocol. J Clin Oncol. 2005;23 (27):6489-98.
11. De Moerloose B, Suciu S, Bertrand Y, Mazingue F, Robert A, Uyttebroeck A, et al. Children's Leukemia Group of the European Organisation for Research and Treatment of Cancer (EORTC). Improved outcome with pulses of vincristine and corticosteroids in continuation therapy of children with average risk acute lymphoblastic leukemia (ALL) and lymphoblastic non-Hodgkin lymphoma (NHL): report of the EORTC randomized phase 3 trial 58951. Blood. 2010;116(1):36-44.
12. Guidal C, Vilmer E, Grandchamp B, Cavé H. A competitive PCR-based method using TCRD, TCRG and IGH rearrangements for rapid detection of patients with high levels of minimal residual disease in acute lymphoblastic leukemia. Leukemia. 2002;16(4): 762-4.
13. Cavé H, Van Der Werff Ten Bosch J, Suciu S, Guidal C, Waterkeyn C, Otten J, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. New Engl J Med. 1998;339:591-8.
14. Vilmer E, Suciu S, Ferster A, Bertrand Y, Cavé H, Thyss A, et al. Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report. Leukemia. 2000;14(12):2257-66.
15. Pui CH, Evans WE. Acute lymphoblastic leukemia. N Engl J Med. 1998;339(9):605-15.
16. Pui CH, Howard SC. Current management and challenges of malignant disease in the CNS in paediatric leukaemia. Lancet Oncol. 2008;9(3):257-68.
17. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47(1):207-14.
18. Kalbfleisch JD, Prentice RL. The clinical analysis of failure time date. 2nd ed. New-Jersey: Wiley Inter-Science; 2002.
19. Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. Trials. 2010;11:32.
20. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trial. BMJ. 2010;340:c869.
21. Gaynon PS, Lustig RH. The use of glucocorticoids in acute lymphoblastic leukemia of childhood. Molecular, cellular, and clinical considerations. J Pediatr Hematol Oncol. 1995;17(1):1-12.
22. Gaynon PS, Carrel AL. Glucocorticosteroid therapy in childhood acute lymphoblastic leukemia. Adv Exp Med Biol. 1999;457:593-605.
23. Veerman AJ, Hählen K, Kamps WA, Vanleeuwen EF, de Vaan GA, Vanwering ER, et al. Dutch Childhood Leukemia Study Group: early results of study ALL VI (1984-1988). Haematol Blood Transfus. 1990; 33:473-7.
24. Silverman LB, Gelber RD, Dalton VK, Asselin BL, Barr RD, Clavell LA, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood. 2001;97(5):1211-8.
25. Schrappe M, Zimmermann M, Moricke A, et al. Dexamethasone in induction can eliminate one third of all relapses in childhood acute lymphoblastic leukemia (ALL): results of an international randomized trial in 3655 patients (Trial AIEOP-BFM ALL 2000). Blood (ASH Annu Meet Abstr). 2008;112: 117.
26. Teuffel O, Kuster SP, Hunger SP, Conter V, Hitzler J, Ethier MC, et al. Dexamethasone versus prednisone for induction therapy in childhood acute lymphoblastic leukemia: a systematic review and meta-analysis. Leukemia. 2011;25(8):1232-8.
27. Hurwitz CA, Silverman LB, Schorin MA, Clavell LA, Dalton VK, Glick KM, et al. Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemia. Cancer. 2000;88(8):1964-9.
28. Merryman R, Stevenson KE, Gostic WJ 2nd, Neuberg D, O'Brien J, Sallan SE, Silverman LB. Asparaginase-associated myelosuppression and effects on dosing of other chemotherapeutic agents in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2012;59(5):925-7.
29. Mattano LA Jr, Sather HN, Trigg ME, Nachman JB. Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the Children's Cancer Group. J Clin Oncol. 2000;18(18):3262-72.